|
Daehan Nupharm Records KRW 48.3 Billion in Q1 2024 Sales
2024.05.17
|
|---|
|
Daehan Nupharm recorded KRW 48.3 billion in sales, KRW 4.5 billion in operating profit, and KRW 5.2 billion in net profit for the first quarter of 2024. Following last year’s record-high annual sales of KRW 204.2 billion, the company achieved solid performance driven by strong sales in its core pharmaceutical business. In particular, the newly launched Rapiduo Tab. and well-being injection products have contributed significantly to sales growth. Rapiduo Tab., launched in March, is a treatment for gastroesophageal reflux disease (GERD). It is an improved new drug that combines rabeprazole (PPI) and magnesium oxide, a first-of-its-kind formulation, which reaches maximum plasma concentration within one hour after administration, overcoming the limitation of existing PPI formulations that take 6 to 7 hours to take effect. To expand its growth base, the company is further strengthening R&D efforts across its business divisions, including pharmaceuticals, veterinary medicine, biotechnology, and health functional foods. In addition to Rapiduo Tab., active research is underway on improved combination drugs for hypertension, hyperlipidemia, and obesity. In the veterinary medicine sector, the company is developing various products for both livestock and companion animals. Recently, Daehan Nupharm received regulatory approval for DH Fuzole Tab., a fluconazole-based treatment specifically for Malassezia dermatitis in companion dogs.
The company is also pursuing the construction of a new production facility to support future growth. In addition to investing in R&D, Daehan Nupharm plans to ensure a stable supply of high-quality pharmaceuticals through the new plant, establishing a solid foundation to further increase sales in human pharmaceuticals. |


Home